NovoCure Ltd (NVCR) FY2025 10-K Annual Report
NovoCure Ltd (NVCR) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 26, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
NovoCure Ltd FY2025 10-K Analysis
Business Overview
- • Core business model: Commercialization of TTFields therapy devices (Optune Gio, Lua, Pax) delivering electric fields to kill cancer cells for solid tumor cancers
- • New emphasis on brain metastases from NSCLC with September 2025 Phase 3 METIS trial showing 28% lower risk of intracranial progression; Optune Mya PMA submitted, FDA review ongoing
- • Strategic expansion to pancreatic cancer with 2026 FDA approval of Optune Pax based on PANOVA-3 trial; survival improved to 16.2 vs 14.2 months (p=0.039)
- • Sales force grew to 217 globally as of December 2025; estimated 8,200 GBM, 30,000 NSCLC, 15,000 pancreatic cancer patients in U.S. eligible and seeking treatment in 2026
- • Unusual milestone: simultaneous regulatory progress with multiple devices—PMA filing acceptance for brain metastases (Optune Mya) and first U.S. approval for pancreatic cancer device Optune Pax
Management Discussion & Analysis
- • Revenue and profitability details not provided in the provided MD&A excerpt
- • No segment performance data disclosed
- • Cash flow, capital allocation, and buybacks or dividends details absent
- • Forward-looking guidance or emerging risks not mentioned in the excerpt
Risk Factors
- • FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications
- • Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization
- • Production dependency on third-party manufacturers for sufficient quality and quantity of Products
- • Competition risk from alternative therapies impacting market acceptance despite FDA and CE approvals
- • Historical substantial operating losses with intermittent profits; ongoing high commercialization and R&D expenses
NovoCure Ltd FY2025 Key Financial MetricsXBRL
Revenue
$655M
▲ +8.3% YoY
Net Income
-$136M
▲ +19.2% YoY
Gross Margin
74.5%
▼ -280bp YoY
Operating Margin
-23.5%
▲ +470bp YoY
Net Margin
-20.8%
▲ +708bp YoY
ROE
-40.0%
▲ +681bp YoY
Total Assets
$804M
▼ -35.2% YoY
EPS (Diluted)
$-1.22
▲ +21.8% YoY
Operating Cash Flow
-$49M
▼ -85.9% YoY
Source: XBRL data from NovoCure Ltd FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on NovoCure Ltd
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.